CYTOO Overview

  • Founded

  • 2008

Founded
  • Status

  • Private

  • Employees

  • 36

Employees
  • Latest Deal Type

  • Later Stage VC

  • Investors

  • 4

CYTOO General Information

Description

Developer of cell analysis technology designed to control the cellular microenvironment. The company's technology focuses on the life sciences research community and the culture platform that significantly enhances the physiological relevance of cellular models in comparison to standard techniques used by most laboratories, enabling clients to simply convert poorly predictable and low throughput assays, into reliable and data-rich high content screening efforts.

Contact Information

Website
www.cytoo.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Primary Office
  • 7 parvis Louis Néel, CS 20050
  • Minatec - BHT - Bât. 52
  • 38040 Grenoble
  • France
+33 04 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CYTOO Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 000.00 Completed Generating Revenue
7. Later Stage VC (Series E) 06-Feb-2015 00.000 000.00 000.00 Completed Generating Revenue
6. Secondary Transaction - Private 0000 Completed Generating Revenue
5. Later Stage VC (Series D) 06-Dec-2012 000 0000 000.00 Completed Generating Revenue
4. Later Stage VC (Series C) 21-Nov-2011 000.00 0000 000.00 Completed Generating Revenue
3. Later Stage VC (Series C) 27-Sep-2011 00.000 000.00 0000 Completed Startup
2. Early Stage VC (Series B) 28-Sep-2009 $4.64M $6.05M 000.00 Completed Startup
1. Early Stage VC (Series A) 30-Sep-2008 $1.41M $1.41M 00.000 Completed Startup
To view CYTOO’s complete valuation and funding history, request access »

CYTOO Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series E 000,000 00.000000 00.00 00.00 00 00.00 0.00
Series D 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series C 000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series B 359,841 $0.114851 8% $10.16 $10.16 1x $10.16 15.43%
Series A 264,785 $0.114851 8% $4.27 $4.27 1x $4.27 11.35%
To view CYTOO’s complete cap table history, request access »

CYTOO Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cell analysis technology designed to control the cellular microenvironment. The company's technology focuse
Discovery Tools (Healthcare)
Grenoble, France
36 As of 2023
000.00
00000 00000 000.00

000000

liqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi u
000000000 00000 (000
Palo Alto, CA
00 As of 0000
00000 00000

000000

e magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco labor
0000000000000
Mountain View, CA
00 As of 0000
000000000 -
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CYTOO Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
System Biosciences Venture Capital-Backed Palo Alto, CA 00 00000 00000
00000000 Private Debt Financed Mountain View, CA 00 000000000 -
0-00000 000 Venture Capital-Backed Seattle, WA 00 000.00 00000000000 000.00
000000 00000000000 Formerly VC-backed Zug, Switzerland 000 00000 000000000 00000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 00000000
You’re viewing 5 of 14 competitors. Get the full list »

CYTOO Patents

  • 22

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

CYTOO Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210015807-A1 Alk5 inhibitors as skeletal muscle hypertrophy inducers Pending 23-Mar-2018 0000000000 0
EP-3768320-A1 Alk5 inhibitors as skeletal muscle hypertrophy inducers Pending 23-Mar-2018 0000000000
JP-2021517574-A Alk5 inhibitor as a skeletal muscle hypertrophy inducer Pending 23-Mar-2018 0000000000
EP-3541394-A1 Skeletal muscle hypertrophy inducers Inactive 17-Nov-2016 000000000
JP-2020500198-A Skeletal muscle hypertrophy inducer Pending 17-Nov-2016 A61K31/57 0
To view CYTOO’s complete patent history, request access »

CYTOO Executive Team (15)

Name Title Board Seat Contact Info
Luc Selig Ph.D Chief Executive Officer & Directeur Général
Erwann Ventre Chief Operating Officer
Beatrice Darimont Chief Scientific Officer
Olivier Pasquier Chief Commercial Officer
Matthieu Piel Co-Founder & Advisor
You’re viewing 5 of 15 executive team members. Get the full list »

CYTOO Board Members (5)

Name Representing Role Since
Marc Le Bozec Self Chairman 000 0000
You’re viewing 1 of 5 board members. Get the full list »

CYTOO Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CYTOO Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Entrepreneurs Fund Family Office Minority 000 0000 000000 0
Auriga Partners (Paris) Venture Capital Minority 000 0000 000000 0
Jacques Lewiner Angel (individual) Minority 000 0000 000000 0
Supernova Invest Venture Capital Minority 000 0000 000000 0
To view CYTOO’s complete investors history, request access »

Ready to get started?

Request a free trial